Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Human COVID-19 immunoglobulin (pH4) for intravenous injection
- Development stage
- Unknown
- Lead developer
- Sinopharm Wuhan Plasma-derived Biotherapies
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Human COVID-19 immunoglobulin (COVID-HIG) is a passive immunotherapy developed by Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd. for the treatment of COVID-19. It is a biologic therapeutic consisting of polyclonal antibodies purified from the plasma of healthy donors who have been vaccinated with the BBIBP-CorV (Sinopharm) COVID-19 vaccine. The drug contains high titers of neutralizing antibodies that target multiple components of the SARS-CoV-2 virus, including the spike (S) protein, the receptor-binding domain (RBD), the N-terminal domain (NTD), and the nucleocapsid protein. By binding to these targets, COVID-HIG blocks the interaction between the viral RBD and the human angiotensin-converting enzyme 2 (hACE2) receptor, thereby preventing viral entry into host cells. It is administered intravenously and has been evaluated in Phase II clinical trials for patients with moderate to severe COVID-19.
- Other names
- Human COVID-19 immunoglobulinCOVID-19 hyperimmune globulinCOVID19 hyperimmune globulinCOVID 19 hyperimmune globulinHuman COVID-19 immunoglobulin (pH4)
02
Targets
N (Nucleocapsid protein)S1-NTD (SARS-CoV-2 spike S1 N-terminal domain)RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on Human COVID-19 immunoglobulin (pH4) for intravenous injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Human COVID-19 immunoglobulin (pH4) for intravenous injection.